primary antibodies anti-lysozyme  (Boster Bio)

Journal: ACS Omega

Article Title: Discovery of JAK2/3 Inhibitors from Quinoxalinone-Containing Compounds

doi: 10.1021/acsomega.2c04769

Figure Lengend Snippet: (A) Docking results of quinoxalinone derivatives toward JAK2/3 derived from FlexX docking. (B) Summary of screened compounds toward JAK2/3.

Article Snippet: Primary antibodies against JAK2 (ab108596), p-JAK2 (ab32101; Y1007/1008) were purchased from Abcam.

Techniques: Derivative Assay

Journal: ACS Omega

Article Title: Discovery of JAK2/3 Inhibitors from Quinoxalinone-Containing Compounds

doi: 10.1021/acsomega.2c04769

Figure Lengend Snippet: In vitro study of focused compounds toward JAK2/3 by kinase assay and cell-based assay. (A) In vitro IC 50 values of the potent quinoxalinone derivatives (MN341P, MN390, ST3i, and ST4j) and drugs (tofacitinib and ruxolitinib) toward JAK2/3 (ND = not detected), the IC 50 value of ST4j compound and drugs toward (B) TF1 and HEL, (C) Vero and HepG2 cells, and (D) Western blot analysis in TF1 cells after treatment with ST4j and drugs at various concentrations. * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001 vs tofacitinib, # p ≤ 0.05 and ### p ≤ 0.001 vs ruxolitinib.

Article Snippet: Primary antibodies against JAK2 (ab108596), p-JAK2 (ab32101; Y1007/1008) were purchased from Abcam.

Techniques: In Vitro, Kinase Assay, Cell Based Assay, Western Blot

Journal: ACS Omega

Article Title: Discovery of JAK2/3 Inhibitors from Quinoxalinone-Containing Compounds

doi: 10.1021/acsomega.2c04769

Figure Lengend Snippet: (A) Per-residue decomposition free energy (Δ G bind residue ), the van der Waals (vdW) and electrostatic energy contributions of the domain of JAK2 for the binding of tofacitinib and ST4j. (B) the binding orientation of ruxolitinib and ST4j within the binding pocket drawn from the last MD snapshot. The lowest and highest energies are colored from purple to dark red, respectively.

Article Snippet: Primary antibodies against JAK2 (ab108596), p-JAK2 (ab32101; Y1007/1008) were purchased from Abcam.

Techniques: Binding Assay

Journal: ACS Omega

Article Title: Discovery of JAK2/3 Inhibitors from Quinoxalinone-Containing Compounds

doi: 10.1021/acsomega.2c04769

Figure Lengend Snippet: (A) Percentage of hydrogen bond occupation of ruxolitinib and ST4j within the JAK2 binding pocket. Note that the hydrogen bond with value >50% was selected to represent in 3D and (B) B factor of JAK2, the flexible and rigid regions are ranged from blue to green and red, respectively. The data were derived from the last 100 ns of the one simulation of JAK2 with ruxolitinib (run 1) and ST4j (run 2).

Article Snippet: Primary antibodies against JAK2 (ab108596), p-JAK2 (ab32101; Y1007/1008) were purchased from Abcam.

Techniques: Binding Assay, Derivative Assay

Journal: Inflammopharmacology

Article Title: Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome

doi: 10.1007/s10787-022-00956-6

Figure Lengend Snippet: Effect of Lira on Cup-induced microgliosis. Representative images of anti-Iba-1 Immunohistochemical staining of brain corpus callosum sections of C57Bl/6 mice (magnification, × 50). a Normal control group, b Cup-, c Lira-, d Lira + Dorso-treated groups, and e Box plot chart for the count of active microglial cells that positively express Iba-1 in six random corpus callosum fields per tissue section. Vertical bars represent the median and range of each group. ( +) represents the mean. Values are statistically significant at P < 0.05 using Kruskal–Wallis ANOVA followed by Dunn’s post hoc statistical tests

Article Snippet: Unstained deparaffinized 5 μm-thick brain tissue sections were cut and processed with 3% hydrogen peroxide for 20 min, washed by PBS, and incubated with ionized calcium-binding adaptor molecule 1 (Iba-1) primary antibody (Abcam, USA, Catalogue No. ab108539) overnight at 4 °C after 1:100 dilution.

Techniques: Immunohistochemical staining, Staining